BioSpace News Archive

icometrix, the world leader in imaging AI solutions for people with neurological conditions, announces a partnership with Aidoc, a leading provider of enterprise AI solutions for medical imaging.

Alchemab Therapeutics today announced the appointment of Douglas A. Treco, PhD as Chief Executive Officer.

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio, a clinical-stage messenger RNA therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company focused on treating diseases of the eye, announced the company has entered a research collaboration with Children’s Medical Research Institute in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies.

The cooperation between Inventum Genetics and the University of Marburg is a long-term agreement.

Fact MR: The global acute care market is expected to grow at high CAGR in the assessment period, from 2021 to 2031 due to rising demand for treatment of cardio vascular diseases.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it has entered into an agreement to acquire Toulouse, France based Polymem S.A., a leading industrial expert in the development and manufacture of hollow fiber membranes and modules.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, provided an update on the clinical advancement of OPC1, its investigational allogeneic oligodendrocyte progenitor cell transplant therapy for the treatment of spinal cord injury.

Applied Genetic Technologies Corporation announced that Jill Dolgin, PharmD, Executive Director of Global Patient Advocacy, will address optometric graduate students on the topic of inherited retinal diseases at the 124th Annual American Optometric Association Congress & 51st Annual American Optometric Student Association Conference: Optometry’s Meeting®, being held June 24-26 in Denver.

Emalex Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that its Phase 2b clinical trial evaluating the efficacy and safety of ecopipam for the treatment of pediatric patients with Tourette Syndrome has reached 100% percent enrollment.